NCT03739931: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies

NCT03739931
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Active central nervous system tumors or metastases
https://ClinicalTrials.gov/show/NCT03739931

Comments are closed.

Up ↑